HC Restrains NPPA from Action against AstraZeneca

What happened

The Delhi High Court temporarily stopped the National Pharmaceutical Pricing Authority from taking coercive action against AstraZeneca Pharma India over recovering more than Rs 151 crore in an alleged drug overcharging case. The order lasts until January 11, the next hearing date.

Confirmed

Global impact / market context

The case tests whether AstraZeneca's Symbicort Turbuhaler inhaler falls under price controls, which cap what companies can charge. If the court agrees with AstraZeneca, it limits the company's payment risk and shows how drugmakers can challenge pricing authority demands using product classification.

Analyst inference

India's pricing authority sets maximum prices for certain medicines under the Drugs (Price Control) Order, 2013, which means listed products face capped revenue per sale. Companies making inhalers could watch this ruling because it clarifies which combination products fall inside those price caps and which stay outside.

Analyst inference

What to watch

1. The Delhi High Court will hear the case again on January 11, when the next order or direction in AstraZeneca's petition against the pricing authority may come. Confirmed
2. AstraZeneca could argue that its Symbicort Turbuhaler 160/4.5 inhaler is not a controlled formulation, which means the pricing authority's overcharging claim and recovery demand should be set aside. Proposed
3. If the court lifts the restraint, AstraZeneca may face pressure to pay the Rs 151 crore demand or book a provision, which means setting aside money in its accounts for a possible liability. Analyst inference

Evidence

• Original source link unavailable